These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
640 related articles for article (PubMed ID: 14988381)
21. The generation of highly enriched osteoclast-lineage cell populations. Quinn JM; Whitty GA; Byrne RJ; Gillespie MT; Hamilton JA Bone; 2002 Jan; 30(1):164-70. PubMed ID: 11792580 [TBL] [Abstract][Full Text] [Related]
22. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. Zou W; Hakim I; Tschoep K; Endres S; Bar-Shavit Z J Cell Biochem; 2001 Jun 26-Jul 25; 83(1):70-83. PubMed ID: 11500955 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. Nagata N; Kitaura H; Yoshida N; Nakayama K Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278 [TBL] [Abstract][Full Text] [Related]
24. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. Feng X; Takeshita S; Namba N; Wei S; Teitelbaum SL; Ross FP Endocrinology; 2002 Dec; 143(12):4868-74. PubMed ID: 12446614 [TBL] [Abstract][Full Text] [Related]
25. [Effect of lipopolysaccharide on osteoclasts formation and bone resorption function and its mechanism]. Zeng L; Xu Y; Xing G Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2018 May; 32(5):568-574. PubMed ID: 29806344 [TBL] [Abstract][Full Text] [Related]
26. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. Kondo H; Guo J; Bringhurst FR J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438 [TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342 [TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures. Uchiyama S; Yamaguchi M Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845 [TBL] [Abstract][Full Text] [Related]
29. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. Shibata T; Shira-Ishi A; Sato T; Masaki T; Masuda A; Hishiya A; Ishikura N; Higashi S; Uchida Y; Saito MO; Ito M; Ogata E; Watanabe K; Ikeda K J Bone Miner Res; 2002 Apr; 17(4):622-9. PubMed ID: 11918219 [TBL] [Abstract][Full Text] [Related]
30. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200 [TBL] [Abstract][Full Text] [Related]
31. Presence of osteoclast precursors in colonies cloned in the presence of hematopoietic colony-stimulating factors. Yamazaki H; Kunisada T; Yamane T; Hayashi SI Exp Hematol; 2001 Jan; 29(1):68-76. PubMed ID: 11164107 [TBL] [Abstract][Full Text] [Related]
32. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985 [TBL] [Abstract][Full Text] [Related]
33. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334 [TBL] [Abstract][Full Text] [Related]
34. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166 [TBL] [Abstract][Full Text] [Related]
35. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Takahashi N; Udagawa N; Suda T Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918 [TBL] [Abstract][Full Text] [Related]
36. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. Li P; Schwarz EM; O'Keefe RJ; Ma L; Boyce BF; Xing L J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390 [TBL] [Abstract][Full Text] [Related]
37. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. Abu-Amer Y; Abbas S; Hirayama T J Cell Biochem; 2004 Nov; 93(5):980-9. PubMed ID: 15389885 [TBL] [Abstract][Full Text] [Related]
38. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680 [TBL] [Abstract][Full Text] [Related]
39. Regulation of osteoclastogenesis by integrated signals from toll-like receptors. Krisher T; Bar-Shavit Z J Cell Biochem; 2014 Dec; 115(12):2146-54. PubMed ID: 25079212 [TBL] [Abstract][Full Text] [Related]
40. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis. Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]